General Archives

General

Additive Manufacturing in Dentistry

May 20, 2023

Dentistry seems to be the potential breakthrough industry to manifest many 3D printing enthusiasts’ dreams of mass customization, point-of-care delivery, and local manufacturing hub for dental professionals, reducing inefficiency and costs. Over the past several years, 3DHEALS has invited many different stakeholders to share their experiences, ranging from material innovation, and software development, to new clinical workflows. Applications ranging from surgical guides, implants, dentures, and night guards are among the new applications gaining increasing attention either in the startup world or the industry at large, in addition to the existing billion-dollar market of dental aligners. The collective thought is that 3D printing can do more and more in parallel to the maturation of technologies. In this 90-minute webinar, we invite experts with unique perspectives about the current status and near future of dental 3D printing, including international clinicians, startup founders, and industry veterans.

Speakers:

Dr. Ioanna Gidarakou

Dr Ioanna Gidarakou received her dental degree from the Aristotle University of Thessaloniki, Magna Cum Laude. She then completed her orthodontic specialty at Eastman Dental Center, University of Rochester, NY. At the same time, she received her TMJD degree and completed a 1-year fellowship on genetics at the Pediatric Department, School of Medicine, University of Rochester, NY. She pursued her PhD thesis on Class II growing patients at the Aristotle University of Thessaloniki. Dr Gidarakou has been actively involved in academics, teaching pre- and post-graduate students, giving lectures worldwide and publishing numerous articles in prestigious orthodontic journals. She currently maintains 2 orthodontic practices in Katerini and Litochoro, in Central Macedonia, Greece. She is married with 3 children.

Gustavo Mendonca

Dr. Gustavo Mendonça is a Professor at the Department of General Practice at the Virginia Commonwealth University. He received his DDS from the Federal University of Uberlandia, Brazil. He also completed his postgraduate training in Prosthodontics and master’s degree in Oral Rehabilitation from the same school. In 2008 he finished his PhD in Genomic Sciences and Biotechnology at the Catholic University of Brasília, Brazil. Dr. Gustavo Mendonça is also a Fellow and a Diplomate of the Academy of Osseointegration. Dr. Gustavo Mendonça’s research interests focus has been related to the use of CAD/CAM materials and 3d printing for clinical use in dentistry and research applications. He also has worked in vitro and in vivo on the effect of osseointegration of implants and biomaterials. In addition to his research, Dr. Mendonça is dedicated to teaching and mentoring the next generation of dental professionals. Dr. Mendonça is passionate about providing high-quality, patient-centered care and ensuring that his students are well-prepared to meet the challenges of the dental profession.

Iain Mcleod

Iain is originally from Scotland and studied B.Eng. Computer Engineering and Electronics at Napier University Edinburgh. On graduating in 1994, he became a founder of a software company specialising in hardware simulation. He then moved to Denmark in 2004, joining 3Shape back in 2007 to develop 3D scanning and CAD software for the digital workflow in audiology. After completing an MBA at Copenhagen Business School in 2019, he got even closer to the world of 3D printing and material development with joining the 3D printer company Formlabs. Iain is now the CEO of H3D, a SaaS company that has developed a fully automated high volume AI solution that removes the need to use CAD software in the digital dentistry workflow.

Dr. Khaled Kasem

Dr. Khaled Kasem has more than 25 years of experience in his field. He currently works exclusively in orthodontics being the chief of orthodontists at Impress while also combining his work at the University of Barcelona as research coordinator in the orthodontic
department. He has studied a master’s degree in Orthodontics and has a diploma in advanced techniques in dentistry. He has publications in renowned journals such as the American Journal of Orthodontics & Dentofacial Orthopedics or Photomedicine & Laser Surgery.

Impress is the #1 European digital orthodontic brand. The company was established in Barcelona in 2019, and since then it has revolutionized the invisible orthodontic sector with the best team of professionals specialized in making people smile and the latest technology applied to the diagnosis, treatment, and follow-up of all cases. In 4 years, Impress has managed to position itself as the European leader in the orthodontic sector with its award-winning invisible orthodontic treatment.

After raising $125 million earlier in 2022, the funding was earmarked to further expand its presence across Europe, as well as propel the orthodontic experience further into the digital realm. Impress is currently present in more than 160 cities in 8 different countries: Spain, Portugal, Italy, United Kingdom, France, Ukraine, Germany and the United States.

Gino Balistreri

Global Market Development Lead – HP Personalization & 3D Printing

Gino Balistreri is engaging with organizations in the dental and medical industry to increase the rate of additive manufacturing adoption, particularly focusing on orthodontic production applications using HP’s Multi Jet Fusion 3D printing technology. Driven by his dedication to healthcare and his mission to enhance quality of life through new technology, Gino has successfully steered cross-functional teams to grow strategic customers to high-volume additive production in fleets with HP’s 3D printers.

Prior to leading a team in developing production applications, Gino served as a Global Product Manager, where he effectively led teams in launching products that automated key steps in scaling MJF production at HP’s largest customers across various industries.

Gino pursued his studies at universities in the Netherlands, Hong Kong, and Mexico, obtaining an MSc and BSc in Industrial Engineering and Management from the University of Twente.

Moderator:

Dr. Jenny Chen

Dr. Jenny Chen is trained as a neuroradiologist, and founder/CEO of 3DHEALS. Her main interests include next-generation education, 3D printing in the healthcare sector, automated biology, and artificial intelligence. She is an angel investor who invests in Pitch3D companies.

3D Bioprinting for Drug Discovery and Development

May 6, 2023

3D bioprinting is a relatively new technology that has the potential to revolutionize drug discovery and development. Here are some ways 3D bioprinting can help in this field: 1) Generating realistic in vitro models: 3D bioprinting can create three-dimensional tissue structures that closely mimic the in vivo environment. These structures can be used to test the efficacy and toxicity of drugs in a more realistic setting than traditional two-dimensional cell culture methods. This can help researchers identify promising drug candidates earlier in the drug development process, which can save time and resources. 2) Personalized medicine: 3D bioprinting can be used to create patient-specific tissues or organs for drug testing. This can help identify drugs that are effective for a particular patient population, as well as identify potential adverse effects that may not be detected in traditional preclinical testing. 3) High-throughput screening: 3D bioprinting can enable the creation of large numbers of complex tissue models in a relatively short amount of time. This can allow for high-throughput screening of potential drug candidates, which can speed up the drug discovery process and reduce costs. 4) Target identification: 3D bioprinting can help researchers identify new drug targets by enabling the creation of more complex tissue structures that better mimic the in vivo environment. This can provide researchers with a more complete understanding of disease biology and help identify new therapeutic targets. 5) Overall, 3D bioprinting has the potential to improve the drug discovery and development process by enabling the creation of more realistic in vitro models, accelerating the drug discovery process, and improving patient outcomes through personalized medicine. In this highly anticipated event, we invite critical stakeholders in the 3D bioprinting drug development ecosystem to update the community on where we are in terms of technologies and commercialization of the technologies.

Speakers:

Andrew Lee

Andrew Lee is a co-founder at FluidForm, a 3D biofabrication company looking to change the way we think about tissue engineering and regenerative medicine. He currently is the Product Manager for the Cardiac Group at FluidForm. He received his Ph.D. in Biomedical Engineering at Carnegie Mellon University where his focus on muscle tissue engineering leveraged biofabrication to create skeletal and cardiac tissue models with complex tissues architecture as well as physiologically relevant contractile functions. This work resulted in a publication in the journal Science and is now utilized as the platform technology for FluidForm as it builds out a portfolio of tissues for research, repair, and replacement.

Kevin Vos

Kevin is the Director of Preclinical R&D at VoxCell BioInnovation. He acquired his Bachelor’s of Science from the University of Victoria in Biochemistry. He then completed his Ph. D. also from the University of Victoria in physical chemistry studying the photo-physical characterization of supramolecular complexes. After his Ph.D., Kevin completed a post-doctoral fellowship at the University of Calgary working with the World Health Organization studying the decontamination and reuse of PPE during the SARS-CoV-2 pandemic. Kevin then joined VoxCell in December 2021, as a tissue engineering scientist where he now leads the development of VoxCell’s tissue models.

Orquidea (Orchid) Garcia, PhD, MS

As a Johnson & Johnson Fellow and Lead for 3D Bioprinting and Tissue Regen Technologies, Orquidea (Orchid) Garcia is the technical lead for 3D bioprinting, and related tissue regen technology development. She is responsible for evaluation and execution of technical strategies and new technology integration to develop a new class of next-generation healthcare solutions. Orchid works closely with internal business partners, as well as technology, academia and government partners to develop J&J’s bioprinting capabilities.

Orchid has extensive experience identifying novel technologies through scientific discovery and translating them into patentable, marketable technologies both in industry and academia. Having served as the scientific subject matter expert on numerous initiatives, she brings a keen understanding of world-wide technical, scientific, regulatory and policy issues that face the business. Orchid has also held various positions within J&J and in industry in Clinical Affairs, Medical Affairs and Regulatory Affairs.

Isabella Bondesson

Isabella Bondesson is a Field Application Scientist at CELLINK, the global leading bioprinting company. Isabella has a BioTech Engineering degree from Chalmers Institute of Technology, and she joined CELLINK in 2018 as part of the R&D team to develop novel methods in tissue model printing. During her time at CELLINK Isabella has acquired expertise in multiple areas of bioprinting and is today leading the EMEA Application team who work with consulting, educating, and supporting customer needs within various aspect of 3D Bioprinting. As the leading 3D bioprinting company, CELLINK is committed to providing the most advanced 3D bioprinting products, services and technologies needed to understand and master biology. CELLINK develops technologies that democratize 3D bioprinting – providing the leading researchers in the world the tools they need to create the future of health.

Moderator:

Dr. Jenny Chen

3D Printing and Bioprinting Bones

April 15, 2023

3D printing and bioprinting to regenerate bone both are promising for the regeneration of bone tissue. It uses 3D printing to create acellular scaffolds or 3D bioprinting bio-inks that contain living cells and growth factors to promote bone growth. This technology has the potential to create exact replicas of damaged bone, which could then be implanted in the body to help regenerate lost tissue. The process begins with scanning the bone defect to create a 3D model of the desired bone structure. Then, biomaterials or bio-ink containing stem cells and growth factors are printed in the desired structure based on the 3D models. The scaffold acts as a supportive structure for the cells, which are then allowed to grow in the desired shape. Once the cells have grown and matured, they can then be implanted into the patient’s body. This technology has been successfully used to regenerate bone in animals and is now being tested in human clinical trials. Some of the forerunners in the field include Osteopore (Singapore), Ossiform(Denmark, previously known as Particle 3D), DimensionInx(U.S., Chicago), and Cerhum(Belgium). In this upcoming virtual event, we invite all stakeholders with different backgrounds to learn and participate focusing on how we can use 3D printing to regenerate bone tissues.

Speakers:

Raphael Lichtnecker

I got my Master´s degree in Pharmaceutical Bioprocess Engineering at Technical University Munich. Afterwards I started as Business Development Manager at ViscoTec where I am responsible for the technology transfer of the progressive cavity pump to the bioprinting sector. I´m in this position for almost five years now.

Elisabeth Cobraiville

Elisabeth is a biomedical engineer specialized in biomaterials. She also holds a university certificate in Quality, Regulatory and Clinical Affairs of medical devices. Prior to joining CERHUM, she worked in a CRO and managed preclinical and clinical trials. She joined CERHUM almost 4 years ago and she is in charge of the products technical file, animal studies and clinical trials.

Daniel Kelly

Prof Daniel Kelly leads a multidisciplinary musculoskeletal tissue engineering group based in the Trinity Centre for Biomedical Engineering. The goal of his lab is to understand how environmental factors regulate the fate of adult progenitor cells and the tissues they produce. This research underpins a more translational programme aimed at developing novel tissue engineering and 3D bioprinting strategies to regenerate damaged and diseased musculoskeletal tissues. To date he has published over 200 articles in peer-reviewed journals. He is the recipient of four European Research Council awards (Starter grant 2010; Consolidator grant 2015; Proof of Concept grant 2017; Advanced grant 2021).

Denys Gurak

Denys Gurak is an experienced C-level manager and serial entrepreneur. He is a CEO and Co-Founder at A.D.A.M., a 3D bioprinting company with a primary focus on 3D-printed bones. Denys’s ultimate vision is to build an on-demand personalized tissue manufacturing platform that would be a one-stop shop for transplanted tissues and organs; and, hence, to cut barriers to medical treatment for millions. Denys’s passion for biotech can be traced back to 2010, when he was leading the international relations and certification, along with EU legislation adaptation at the Ukrainian medicinal products regulatory authority (official position – director of the «GMP/GDP Center» of the State Administration of Ukraine on Medicinal Products (SAUMP). In 2014 Denys joined the Ukrainian Defense Industry (a state defense conglomerate) in 2014 as the Deputy Director-General for foreign economic activity. During his time at the company, he managed the export-import operations that amounted to USD 1 billion yearly turnover. Furthermore, Denys represented Ukraine as the Head of Ukraine’s delegation to the NATO Industrial Advisory Group (NIAG), and led the industry transformation initiatives, including innovations development and technology JVs, as well international relations. Denys is a Venture Partner at ff Venture Capital a high-performing early stage venture firm based in NYC and Warsaw, Poland, focusing on disruptive IT, biotechnology, aerospace and security projects in CEE region.

Dan Rogozea

Dan Rogozea started working in the bioprinting field with the mission to produce the smallest bones in the human body, the ossicles. This project started in 2018 and initiated his work in the bioprinting field. In collaboration with Dr. Moldovan at the Roudebush VA Medical Center Bioprinting Core, he has continued to work in multiple projects in different fields ranging from cardiovascular to dental bioprinting projects. As an expert in the field Dan Rogozea continues to work in research and for well -known bioprinting companies.

Moderator:

Dr. Jenny Chen

3DHEALS World Community Managers Festival

April 1, 2023

Since 2018, 3DHEALS has decentralized its community activities from San Francisco, California, USA, to more than twenty cities throughout the world. This growth was mostly organic by motivated and special individuals, 3DHEALS Community Managers, who came from all walks of life ranging from techies, and designers, to entrepreneurs, doctors, and investors. The goal of these local groups and events aims to bridge the knowledge and experience gap between 3D printing, an emerging technology, and the established healthcare and life science innovation ecosystem. It takes a village to make things happen! On February 23rd, 2023, we will invite these local communities into our virtual arena on Zoom Event by hosting two one-hour virtual events (9-10 AM, and 4-5 PM Pacific Standard Time). We would like to invite our entire healthcare 3D printing and bioprinting ecosystem to meet our community managers from all over the world after a long hiatus due to the pandemic. We anticipate a revival of in-person events and likely hybrid events later this year. We will provide our audience with a new and unique experience through our new Zoom Event platform, with more ways to engage fellow attendees. We will get our community managers and local partner organizations to update us first and then attendees can freely visit the community “booths” and connect in small groups.

Speakers:

Vidya Chamundeswari Narasimhan

Dr. Vidya Chamundeswari Narasimhan is a Process Development Manager at STEMCELL Technologies, where she manages a team of Associates focused on the technology transfer of new products in the liquid cell culture Media Product Portfolio! She has previously worked as a division lead scientist at New Age Meats, developing food-grade matrices and culture media for cultivated cells. Vidya obtained her Doctorate by Research from Nanyang Technological University. Her Ph.D. work focused on developing bioactive polymeric scaffolds for tissue regeneration applications. She has interned at reputed universities and institutions such as MIT-Harvard (2013) and National Chemical Laboratory, Pune India (2012). She was the title winner of the Young Persons’ World Lecture Competition, in Australia (2017), and a finalist at the Falling Walls Lab Competition in Singapore (2019). At 3DHEALS, Vidya served as the Community Manager – San Francisco from 2019 – to 2022. She has contributed to expert corner blogs and organized networking events. She is currently based in Vancouver and is working towards setting up a 3DHEALS hub on the West Coast of Canada.

Ben Holmes

Dr. Benjamin Holmes is a seasoned entrepreneur, C-level executive, and inventor. He is the founder and CEO of Nanochon, a spin-out from his from lab at The George Washington University. He is also a founder, member of the board and executive at several other medical device and regenerative medicine companies. His PhD is in Mechanical Engineering, and focused on biomaterials and 3D printing for complex tissue regeneration and drug delivery.

Bill Harley

William is a Ph.D. candidate within the School of Biomedical Engineering at the University of Melbourne. He obtained a certificate 3 in business management and an honors degree in medical biotechnology from the University of New South Wales where he first entered research focusing on biomaterials, stem cells, and nanofabrication processes for tissue regeneration. Currently, his Ph.D. investigates the use of acoustic micromanipulation and 3D bioprinting as tools to pattern and define the cellular microenvironment. William has held roles as a research assistant and a business development consultant, where he currently serves as a community and events manager for 3D Heals and an organizing committee member for the Australian Bioprinting Workshop.

Dr. Ho Chaw Sing

Dr Ho Chaw Sing is the CEO of the National Additive Manufacturing Innovation Cluster (NAMIC), a Singapore government platform he co-founded as Managing Director at NTUitive in 2015 to catalyse innovation and scale industrial adoption of digital additive manufacturing technologies. Since its inception, NAMIC has orchestrated hundreds of public-private partnerships focusing on translational research to develop and deploy industry-relevant AM technologies and solutions across multiple industry sectors. Before joining the public sector, Chaw Sing was Head of Innovation and Strategic Partnerships at HP Singapore, Printing and Personal Systems Group. Prior to this, he was the Global Head for Consumer Inkjet Supplies Business operations, overseeing manufacturing supply chain operations and product innovation in HP. Chaw Sing began his career in the semiconductor industry with Chartered Semiconductor Manufacturing – now part of GlobalFoundries, in various customer-facing technology and engineering operation leadership roles.

Christle Koh

Christle Koh is the Head of Events and Marketing of the National Additive Manufacturing Innovation Cluster (NAMIC), a Singapore government platform formed to catalyse innovation and scale industrial adoption of digital additive manufacturing technologies. Since its inception in 2015, NAMIC has orchestrated hundreds of public-private partnerships focusing on translational research to develop and deploy industry-relevant AM technologies and solutions across multiple industry sectors. Prior to joining NAMIC, Christle has managed B2B events in various industries including advanced manufacturing, space technology, and transport logistics.

Joseph Borrello

Joe is currently the Lead Biomedical Engineer at Mount Sinai BioDesign, where he also recently received his PhD from the labs of Drs. Kevin Costa and Junqian Xu. In addition to his graduate work and helping lead engineering efforts within the Sinai BioDesign innovation team, Joe has been involved for many years in the leadership of GRO-Biotech, an inter-institutional, student-lead consortium focused on expanding career development opportunities for graduate students in and around the life sciences. More recently, he has also helped start the NYC chapter of Nucleate, a student-lead bio-entrepreneurship program focused on helping first-time scientific founders. Previously, Joe has worked at 3D Systems on technical development in the consumer marketing department and as a liaison with engineering project management teams, in addition to an earlier stint at experiential marketing firm Affinitive. Joe received his bachelors in Biomedical Engineering from Macaulay Honors College at The City College of New York, where he remains active in the Zahn Innovation Center, an on-campus tech startup incubator. He has also been involved in several startup ventures in the hardware and biotech spaces. Several years ago, Joe took Proto-Sauce, through NYCEDC’s Futureworks Incubator, with the goal of developing new materials for resin-based 3D printing. More recently, he had the privilege to serve as the CTO of BioSapien, using advanced manufacturing to create new devices for the treatment of cancer. Beyond his direct startup work, I’ve also continued to participate in Futureworks as a mentor, as well as others within the New York City startup community. Last, but not least, Joe is the writer and publisher of Magnitude and Direction (and it’s long-form companion Moment of Inertia), a bi-weekly email newsletter that focuses on some of my primary areas of interest, including bioengineering, data science, history, and cartography, as well as various events, opportunities, and goings-on in NYC revolving around the city’s growing technology and startup communities.

Ryan Harold

I live in the suburbs of Chicago, which is where I am originally from. I studied mechanical engineering as an undergraduate and then worked for several years as an engineer. I then transitioned into medicine and am an orthopedic surgeon. I focus on shoulder, elbow, and hand conditions. I have had a long interest in 3D modeling and 3D printing, especially as it pertains to orthopedics. 3D printing really combines my love of engineering with my passion for orthopedics.

Zsolt Pásztor

Zsolt is Co-founder and Managing Director of PREMET, a Hungarian MedTech company focusing on the production of medical devices, including patient specific implants, by additive manufacturing. The company puts a high emphasis on the continuous development of all elements of the production workflow – titanium 3D printing, thermal and surface treatment – and has been involved in several international R&D projects. Zsolt plays an important role in the management of the developments, and focuses especially on the improvement of the printing procedure and the different type of surface treatments. He is a Community Manager at 3DHEALS, co-founder and Vice-President of the Hungarian Additive Technology Association, Director of International Affairs and Leader of the “3D Printing in the Health Sector” working group of MediKlaszter, an accredited MedTech cluster. He was the Lead Expert of a recent Transnational Cooperation Project, aiming at collecting and disseminating best practices in the field of 3D Printing in the Health Sector in Central Europe.

Firoza Kothari

Firoza Kothari, Co-Founder & CTO – Anatomiz3D Medtech Pvt. Ltd. – A B.Tech in Biotechnology Engineering and now Forbes 30 under 30 – Asia – Healthcare and Science, 2020, Firoza Kothari started her journey to provide patient-specific medical solutions and one day end the organ donation problem by creating live organs out of patients’ stem cells. With that aspiration, she gave birth to Anatomiz3D, a startup focusing on medical 3D printing. She, along with her team, was the first to execute soft tissue models in India through Paediatric Cardiology, partial amputee prosthetic hand, the first kidney tumor case in India, and the model for tongue cancer was the first in the world. Being a Co-founder and CTO of Anatomiz3D, she, along with her team, has successfully added 3000 plus case studies. Her multi-disciplinary expertise prevails in converting 2D DICOM CT/MRI/Echo Scans to 3D Printed anatomical replicas, medical devices, and allied products, using various combinations of Hardware and Software, across multiple medical specializations. Anatomiz3D has played a vital role in creating the market for 3D Printing in the Medical industry in India since 2015 and is a pioneer for the same, also being the first in India to enable Hospital-Industry partnerships for Point-of-Care Labs.

Rafael Ramos

Reference contact for 3DHEAL for 3DHEALS Detroit/SE Michigan. Currently PhD candidate in Tissue Engineering exploring applications for FDM/SLA Bioprinting modalities to create drug testing template environments. I have some knowledge of the faculty at Wayne State University but I’m very interested in ensuring I have a solid sense of the field in Michigan (all universities and startup culture) and this part of the Midwest if anyone is interested in formalizing this line of communication. I grew up in Mexico City so I have also previously served as a communication link with the burgeoning bioprinting/3d printing culture in Mexico, specifically with some contacts out of the Tecnologico de Monterrey system. Happy to serve as a link to organizations like Latinx in BME and the Latino Medical Student Association. I also do some freelance work in spanish-language STEM communication should that need be usable in some capacity to anyone.

Hannah Riedle

Hannah has a background in mechanical engineering and focused her PhD on 3D printed soft anatomical models. Based on the results of her research she founded ANAMOS, a company developing configurable anatomical models Form surgical simulation.

Jim Long

Innovative therapy Consultant with a proven history of success in the healthcare industry. Passionate about developing and delivering the best solutions for patients. Strong sales professional skilled in: Structural Heart-TAVR, Vascular/Peripheral/Neurointerventional spaces. Actively working to build and strengthen the network of 3D printing in Healthcare!

Dr. Jenny Chen

Dr. Jenny Chen is trained as a San Francisco-based neuroradiologist, and the founder/CEO of 3DHEALS. Her main interests include next-generation education, 3D printing in the healthcare sector, automated biology, and artificial intelligence. She is an angel investor who invests in Pitch3D companies.

3D Printing for Orthopedic Care

March 24, 2023

How useful is 3D printing in healthcare? Beyond the Aligner and hearing aid examples, the field of orthopedic care is perhaps the earliest and biggest adopter of this emerging technology. 3D-printed orthopedic solutions can be used to create customized implants and prostheses that are a perfect fit for each patient. This not only results in a better fit and more comfortable device, but it also leads to potentially faster healing times and longer durability. 3D printing presurgical planning either using anatomical models or surgical guides is now routinely used in the operating room. In this upcoming webinar, we primarily focus on orthopedic surgical care from several different perspectives. In a future webinar in April, we will focus on 3D printing or bioprinting bone tissue using tissue engineering techniques. The commercialization and regulatory pathways for 3D-printed orthopedic implants are approaching maturity, with industry leaders like Stryker, JNJ, and more continuing to expand their 3D printing product and service portfolio. Naturally, this is an active area of innovations and entrepreneurial activities, and investments, since short-term favorable exit is more likely compared to other applications.

Speaker:

David Jansen

David Jansen is the CEO of SAIL Fusion, a company that develops novel sacroiliac fusion devices for spine surgeons built on AO principles. With a background in leading innovation at DePuy Synthes and Globus Medical, David brings a track record of launching innovative new technologies. His team is composed of industry veterans and leading spine surgeons, all working towards major improvements for the treatment of SI joint dysfunction.

Ruben Wauthle

Ruben started his career at LayerWise in Belgium (now 3D Systems) in 2010 as Medical Application Engineer and obtained a PhD in Mechanical Engineering in 2014 from KU Leuven on the topic of selective laser melting of porous titanium and tantalum implants. In 2015, he joined FMI Instrumed in the Netherlands where he started and managed the additive manufacturing division. Ruben returned to 3D Systems in 2017 as a director within the healthcare business unit, and was responsible for all sales in Europe for contract manufacturing and metal printer sales. Ruben is since 2020 co-investor and CEO of Amnovis, a 3D printing contract manufacturing and engineering company.

Brett Carey

Dr. Brett Carey is CEO of Kalo Multispeciality Group based in Kona, Hawaii. His clinic exclusively uses 3D printed hand orthoses for all post operative patients. Kalo has also performed clinical trials with Spentys Orthopedics, trialing Ankle-foot-orthoses within adult patient populations. Additionally, Brett is an Adjunct Professor at Hawaii Pacific University which became the first University to offer additive manufacturing education to Doctor of Physical Therapy students. He serves as a Key Opinion Leader in Orthopedics for Desktop Health and believes that additive manufacturing will help meet overarching healthcare system goals of decreasing cost while bettering patient outcomes.

Frédéric Schuind

Prof Frédéric Schuind is an orthopedic surgeon and professor with a career spanning several decades. He has held numerous positions throughout his career, including the Head of the Department of Orthopaedics and Traumatology at Hôpital Erasme in Belgium and as a Full Professor at the Université libre de Bruxelles. Prof Schuind specialized in orthopedics and traumatology, with a focus on prosthetics. He has been an active member of multiple scientific societies, including the role of President for the Société Royale Belge de Chirurgie Osseuse et de Traumatologie and the Belgian Orthopaedic Trauma Association. Dr. Schuind’s contributions to the field extend beyond his academic pursuits; he has also organized international meetings, undertaken surgical and educational missions in developing countries, and served as a reviewer for various journals.

Moderator:

Dr. Jenny Chen

Canadian Healthcare 3D Printing Ecosystem

February 11, 2023

With a unique and different healthcare system and challenges from its immediate neighbor, the United States, this virtual event invites influencers in the Canadian healthcare 3D printing and bioprinting ecosystem to share with us how they are innovating, thriving, and solving entrepreneurial problems.

Speakers:

Kelly Knights

Kelly Knights is the Chief Operating Officer at Victoria Hand Project, a Canadian charity that provides highly-engineered 3D printed prosthetic arms to amputees in-need, worldwide. Primarily, Kelly focuses on human factors testing and liaison of communication between clinicians, software developers, and engineers. Kelly leads VHP marketing, and assists with fundraising, volunteer coordination, grant-writing, R&D, and supporting VHP international partners. She graduated from the University of Victoria with a B.Eng in Biomedical Engineering, and has been involved with Victoria Hand Project since 2016, filling various roles. Her focus and specialty is cost-effective 3D solutions, scalable to remote and low-income areas, used to create creative healthcare solutions that serve those most in-need.

Mohamed Gamal

Dr. Gamal has spent over a decade working in the pharmaceutical industry as a community pharmacist, product specialist, and pharmaceutical trainer. In 2012, he earned a Master’s Degree in Stem Cells and Regeneration from the University of Bristol. He then obtained a PhD in Biomedical Engineering from the University of British Columbia in 2020. During his PhD studies, he invented and patented a novel way of producing the gelatin methacryloyl (GelMA) hydrogel, which is a versatile biomaterial used in bioprinting and pharmaceutical testing. As the founder and CEO of The GelMA Company, he is committed to making GelMA the most accessible and versatile hydrogel in the world so that more groundbreaking research can occur in the field of biotechnology.

Dr. Stephen Ryan

Dr. Stephen Ryan is a practicing physician and co-founder of PolyUnity Tech. He has explored Additive Manufacturing applications in healthcare for over 6 years as a researcher and entrepreneur. He has been involved in the creation of many 3D Printed products including medical simulations, patient-specific medical devices, PPE, and end-use hospital equipment. To make 3D Printing more accessible to hospitals, his team has built the i3D.Health portal, a digital inventory system for 3D Printable medical equipment. He believes that collaboration and strategic partnerships is the key to creating a thriving 3D printing ecosystem in healthcare.

Keith Ippel

Co-leading Spring Activator and Spring Investing Collective

With over 25 years of experience as a leader in technology & impact businesses and as an angel investor, Keith Ippel has accelerated the growth of both small and large companies and raised over $80M in angel investment and venture capital. Keith has trained more than 400 impact entrepreneurs on investment readiness and raising capital, and co-lead Spring Activator and the Spring Investing Collective

Event Moderator:

Vidya Chamundeswari Narasimhan

Dr. Vidya Chamundeswari Narasimhan is a Process Development Manager at STEMC.ELL Technologies, where she manages a team of Associates focused on the technology transfer of new products in the liquid cell culture Media Product Portfolio! She has previously worked as a division lead scientist at New Age Meats, developing food-grade matrices and culture media for cultivated cells. Vidya obtained her Doctorate by Research from Nanyang Technological University. Her Ph.D. work focused on developing bioactive polymeric scaffolds for tissue regeneration applications. She has interned at reputed universities and institutions such as MIT-Harvard (2013) and National Chemical Laboratory, Pune India (2012). She was the title winner of the Young Persons’ World Lecture Competition, in Australia (2017), and a finalist at the Falling Walls Lab Competition in Singapore (2019). At 3DHEALS, Vidya served as the Community Manager – San Francisco from 2019 – to 2022. She has contributed to expert corner blogs and organized networking events. She is currently based in Vancouver and is working towards setting up a 3DHEALS hub on the West Coast of Canada.

3D Printing and Microfluidics

December 19, 2022

“Microfluidics refers to the behavior, precise control, and manipulation of fluids that are geometrically constrained to a small scale (typically sub-millimeter) at which surface forces dominate volumetric forces…It has practical applications in the design of systems that process low volumes of fluids to achieve multiplexing, automation, and high-throughput screening.” (Wikipedia)

However, most of you are already very familiar with the concept of microfluidics, often appearing as a transparent plastic chip with strategically designed channels and controlled fluid dynamics to manipulate cells or event organoids. The concept of “organ-on-a-chip” is the more popular application in the media. The infamous Theranos touted it as its central technology, which is still considered a myth by experts (we will see). However, many biotechnology companies are now employing microfluidics at scale, and its ecosystem is maturing rapidly. Lately, 3D printing has been both a manufacturing method and an application for microfluidics. Better microfabrication techniques, new biomaterials, and expanded design capabilities add acceleration to its latest growth.

Speakers:

Jan Pal-Goetzen

Jan Pal-Goetzen is the Founder and CEO of 3D printed microTEC ,Bethesda Maryland. The company takes 3D printing beyond rapid prototyping. While pushing the resolution limits down to 1μm lateral, the unique batch approach allows mass volume production on a single 3D-printer. The solutions are always innovative and often groundbreaking in the field. Jan has been in the field of 3D printed microfluidics and packaging of microelectronics for over 10 years. He holds a PhD in Physics from Marburg University Germany.

Paul Marshall

An experienced Chartered Mechanical Engineer, Paul is an engineering consultant specialising in Life Sciences, and co-founder and CEO of Rapid Fluidics. His work focuses on the design and rapid-prototyping of microfluidic systems but also covers a wide range of other projects from medical device design through to technical reviews of water, sanitation and health projects for the Bill and Melinda Gates Foundation.

Cory Lambertson

Cory Lambertson has over 8 years of experience in additive manufacturing. He started his career in the Dental Laboratory Industry after college by joining his Father at Heartland Dental Laboratory in 2013. From there, Cory ventured off into corporate dentistry which is where he was first introduced to the Asiga brand of 3D Printers. Cory found a passion for the Asiga brand of 3D Printers due to the revolutionary changes that they bring to the dental industry. Today, Cory is the General Manager of Americas at Asiga, and is based out of Ann Arbor Michigan.

Gavin Jeffries

Gavin D. M. Jeffries is a Founder and Chief Technology Officer at Fluicell AB. Gavin holds a PhD in Chemistry from the University of Washington and is a former assistant Professor at Chalmers University of Technology. Gavin has published over 40 peer-reviewed publications with a cumulative citation count of over three thousand. As an entrepreneur/founder of two biotech and optics companies and inventor of multiple patents and technologies, Gavin has a strong background in microfluidics, single-cell analysis, and optical platform integration. Fluicell AB is a Life-Science tool company with a commercialized product portfolio of microfluidic products to investigate individual cells, primarily in the fields of drug development and regenerative medicine. Fluicell recently developed a unique high-resolution technology for bioprinting in both 2D and 3D under the name Biopixlar®. Built upon Fluicell’s patented microfluidic technology, Biopixlar can generate detailed, multi-cellular biological tissues, directly in cell culture media, without the use of a bioink. This all-in-one discovery platform helps researchers around the globe to build biological tissues for drug development, disease understanding and regenerative medicine research.

Yang Xu

Yang Xu is a postdoctoral researcher at the Center for Advanced Manufacturing, University of Southern California. He earned an M.S. degree in Computer Science and a Ph.D. degree from USC in 2021. His research interests are novel 3D printing processes for polymers, polymer-based composites, and related applications. His recent work, “In-situ Transfer Vat Photopolymerization for Transparent Microfluidic Device Fabrication”, solved the z-resolution challenge of 3D printing microfluidic devices.

Moderator:

Dr. Jenny Chen

Dr. Jenny Chen is trained as a neuroradiologist, founder/CEO of 3DHEALS. Her main interests include next generation education, 3D printing in the healthcare sector, automated biology, artificial intelligence. She is an angel investor who invests in Pitch3D companies.

Fundraising, Venture Capitalists, Angel Investors in Healthcare 3D Printing

December 2, 2022

One of the most exciting missions at 3DHEALS is discovering early-stage startups, meeting the founders, and helping these companies with fundraising through our Pitch3D program. Our goal is to save the founders and selected institutional investors time to meet each other at the right time along the company’s journey at zero cost to either side. Since April 20th, 2018, 3DHEALS has hosted numerous online and offline Pitch3D sessions regularly, introducing 30+ startups from all over the world to institutional investors who are interested in healthcare 3D printing, bioprinting, and adjacent fields including AI and cybersecurity (within 3D printing), 3D scanning, VR/AR, 3D Visualization, synthetic materials, and regenerative medicine. In this unique 3DHEALS virtual event, we would like you to meet some of the VCs and angel investors behind the scene and learn more about the medical device and biotechnology investment environment under the current macroeconomy. The format of this event will focus on a moderated panel discussion focusing on the current status, short-term, and longer-term outlook of the institutional investment landscape. The audience is welcome to bring many questions to this rare and unique opportunity and engage live.

Speakers:

Tak Cheung

Tak joined NEA in 2018 and is currently a Partner on the healthcare team. He focuses on medical device investments.

Prior to NEA, Tak was a Venture Partner at Merieux Development Venture Fund where he led all phases of investment for healthcare startups, including sourcing, diligence and investment approvals. Tak also co-founded Lexington Medical, a commercial-stage medical device startup in the gastrointestinal surgery space. Prior to Merieux and Lexington, Tak was VP of Business Development for the Global Surgical Division at Bausch & Lomb, and was responsible for all business development efforts in the ophthalmic surgical division. Tak has held various corporate and business development leadership roles at Edwards Lifesciences in the Heart Valve Therapy Division and Advanced Medical Optics (acquired by Johnson & Johnson).

Tak received a BS with Honors in Engineering and Applied Science from the California Institute of Technology, an MD from the University of California, Irvine, and an MBA from Harvard Business School.

Tom Gwinn

Tom Gwinn is an Investment Manager at Evonik Venture Capital (EVC) based in Silicon Valley. Tom has been actively involved in the technology community in the valley for over a decade. Prior to joining Evonik, Tom has held roles in venture capital investing, startup patent strategy, and applied physics research — providing a broad set of experiences to draw upon in support of Evonik’s investments. Tom has a B.S. in Electrical Engineering from Caltech, an M.S. in Electrical Engineering from Stanford, and a J.D. from Stanford Law School.

Tom Vogelsong

Tom is an angel investor in MedTech and a Life Science Advisor to and Director of Deal Flow for Kyto Technology and Life Science (www.kytotech.com). Tom is also an advisor to Medtech Innovator, Silicon Valley Advantage, US Angels, Edge AI and Embedded Vision Alliance, Camdo, InQCel, and Lehigh University’s new College of Health. He received his PhD in Electrical Engineering and has a background in technology, entrepreneurship, medical devices, and biochemistry. Tom scouts early-stage investment opportunities for Kyto in MedTech, BioTech, Diagnostics, and Tech. He has executive experience along with technical expertise and business development background with startups, including as CEO of venture-backed Photon Vision Systems, as well as with medium and large size companies including GE Medical. Tom has invested in startups and helped companies raise capital as well as coaching them to set a vision for growth and making connections for them to achieve success. Tom invests in MedTech and Tech directly as an angel investor and as part of Kyto.

Natalie Levy

Natalie Levy is the Founder of She’s Independent, a women-first investment group offering an entirely new way to support women’s financial independence and influence through investing and board placements. As a member-led investment group, She’s Independent marries empowerment and action, with the ultimate mission of closing the power gap in investing by getting more women on the cap table, in the boardroom, and into positions of influence. Over the next 12 months, She’s Independent plans to deploy $1.5M of capital collectively, and has invested in 9 deals since its formation in January 2022. An accomplished engineer turned Wall Street derivatives trader, investor, and advisor, Natalie has over a decade of tech operational experience, a portfolio of 30+ seed through later stage private investments, and has experienced liquidity events across 3 of the first 4 investments in her growth technology portfolio with an average return >20X. Natalie resides in Boulder, CO with her loving rescue pup Beans and is passionate about gender equity and mental health awareness.

Jimmy Lu

Jimmy is a Co-Founder & Managing Director of Eos BioInnovation, a new venture that incubates projects and invests in early-stage startups in the Regenerative Medicine field originating from top academic and research institutions.

Prior to Eos, Jimmy was a Managing Director/Senior Partner in the San Francisco office of WI Harper, bringing over 25+ years of technology/healthcare and venture capital experience. While at WI Harper, he had been the leader of the healthcare team investing in the medical device, healthcare services and biotech/life science sectors. Jimmy was a Board Director of DeepBiome Therapeutics, Panorama Medicine, Kindstar Globalgene Technology, China Diagnostics Medical Corporation (Chemclin), StemCyte Inc., and Circle Pharma.

Before joining WI Harper, Jimmy co-founded and was a General Partner of iD Ventures (Acer Technology Ventures), with key investments that included iRobot Corporation, Harmonix Music, Monolithic Power Systems, and Fortinet.

Jimmy earned a BA from Yale College, an MBA from Harvard Business School and a JD from UC Berkeley School of Law. He serves on the University of Florida College of Engineering West Coast Advisory Board, and he is a member of the advisory board of Elm Street Ventures and is Co-Chair of the Investment Committee for the National Foundation for Cancer Research AIM-HI Accelerator Fund (Women’s Venture Competition).

Arno Held

Arno Held is Managing Partner of AM Ventures and specializes on the firm‘s ecosystem, as well as its global footprint and organizational growth. He started AM Ventures together with Johann Oberhofer in 2014. In total, Arno has more than 23 years of experience in industrial laser and manufacturing technologies and spent more than half of this time in the world of industrial 3D printing.

Since founding AM Ventures, Arno has been instrumental in building the AM Ventures team that has scouted more than 2,500 3D printing startups all over the world, conducted more than 35 rounds, built a €100m VC fund and today holds a portfolio of 17+ shareholdings in 6 countries on 3 continents.

Arno holds a diploma degree in industrial engineering and management from the University of Applied Sciences Karlsruhe (Germany) as well as an international executive MBA from the University of St. Gallen (Switzerland). Arno completed his studies in Shanghai, China and Cape Town, South Africa.

Moderator:

Dr. Jenny Chen

Point of Care 3D Printing

November 16, 2022

Point of care 3D printing is becoming one of the biggest attractions in adopting 3D printing in healthcare systems because it demonstrates the ability to decentralize manufacturing personalized medical devices. The medical devices can range from anatomical modeling, and implants, to surgical guides based on the latest updates from all over the world. However, for companies interested in expanding markets either locally or regionally, understanding the complex relationships among different players and regulations are critical.

At the end of 2021, the FDA published its discussion paper on the subject, inviting the public to submit comments so that more clarifying regulatory guidance can be created.

Speaker:

Ido Bitan

Ido Bitan is a Product Manager in Stratasys’s Medical Solutions Department. Mr. Bitan received a Bachelor of Science in biomedical engineering from Beer Sheva University in Israel. Mr. Bitan began his career at a start-up company, where he worked as part of the Research & Development team to develop new cancer-detecting equipment that assists surgeons in the operating room. Mr. Bitan has helped establish Stratasys’s adaption to the medical industry, leading the development of the Digital Anatomy Printer, Digital Anatomy Creator, and many more of the accompanying materials and software features. The Medical Department at Stratasys continues to push the boundaries of technology to improve patient care worldwide, and Mr. Bitan is passionate about improving the healthcare system to ensure better outcomes for any patient.

Martin Herzmann

Martin Herzmann started his medtech career in 1999 at Brainlab Headquarter in Germany. After wworking positions in Sales, Product Management and Business Development, he joined Ziehm Imaging in 2007 and worked for another eight years as Marketing Director for medical capital equipment. In 2015, he joined the Materialise and transformed his past experiences into medical 3D printing. In 2019, Martin joined Kumovis as Business Development Manager. The company enables medical device companies and hospitals to manufacture 3D printed implants, instruments and guides following regulatory standards and norms. Kumovis has a clear focus on medical 3D printing with high-performance polymers and biodegradable polymers. With the merger of Kumovis and 3D Systems in April 2022 Martin now can focus even more on additive manufacturing at Point-of-Care and accelerates the global implementation of clinical applications such as cranial implants printed in PEEK.

Kerim Genc

Kerim Genc is the Business Development Manager for the Simpleware Product Group at Synopsys. He joined Simpleware in 2011 as a Technical Sales Consultant and is currently responsible for managing global sales, business development and partnerships. He received his BS and MS in biomechanics from the University of Calgary and the Pennsylvania State University respectively and completed his PhD in Biomedical Engineering at Case Western Reserve University looking at countermeasures to spaceflight induced bone loss and fracture risk.

Silvina Zabala-Travers

– MD and Radiologist Degree from Universidad de la República (UdelaR) in Uruguay – 3D training at Sant Joan de Déu Hospital 3D Lab (Expert3D and internship) in Barcelona, Spain Dr Zabala-Travers introduced 3D technologies to the academic medical field in Uruguay in 2019 and has since pioneered its development with particular interest in training radiologists to be part of the workflow to ensure process precision. She founded and leads the Surgical Virtual Planning and 3D Printing Area at the Radiology Department Pereira Rossell Hospital Center, a state and university laboratory for the application of 3D technologies in diagnostics, surgical virtual planning, clinical simulation and education for pediatric and adult patients. She recently teamed-up with a custom-implant manufacturer to co-found UPGRADE Medicals, a healthcare 3D-technology start-up which provides anatomical biomodels, virtual planning with surgical guide design and custom implant in metal, PEEK and bioabsorbable materials. She is invited professor at the Expert3D course and has given many conferences sharing her experience implementing a hospital 3D lab in a low-resource facility, as well as hands-on training on segmentation, biomodeling and virtual planning for bioengineers and surgical specialists. She presides the Latin American Society of Pediatric Radiology (SLARP) New Technologies Committee, a network for the implementation of 3D technologies in Latin American countries. She also works as Radiology Section Editor for the Elsevier Journal Annals of 3D Printed Medicine, currently Guest Editor for the Special Issue “Virtual Planning and Personalized Medicine”.

Course Category: General

General

Speakers:

Moderator:

Speakers:

Moderator:

Speakers:

Moderator:

Speakers:

Speaker:

Moderator:

Speakers:

Event Moderator:

Speakers:

Moderator:

Speakers:

Moderator:

Speaker:

Ido Bitan

Moderator: